<?xml version='1.0' encoding='utf-8'?>
<document id="31493066"><sentence text="Methotrexate Reduces the Clearance of Adalimumab by Increasing the Concentration of Neonatal Fc Receptor in Tissues."><entity charOffset="0-12" id="DDI-PubMed.31493066.s1.e0" text="Methotrexate" /></sentence><sentence text="Although pharmacokinetic (PK) interaction effects of methotrexate (MTX) on adalimumab have been found, the mechanism of these effects is still unclear"><entity charOffset="53-65" id="DDI-PubMed.31493066.s2.e0" text="methotrexate" /><entity charOffset="67-70" id="DDI-PubMed.31493066.s2.e1" text="MTX" /><entity charOffset="75-85" id="DDI-PubMed.31493066.s2.e2" text="adalimumab" /><pair ddi="false" e1="DDI-PubMed.31493066.s2.e0" e2="DDI-PubMed.31493066.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31493066.s2.e0" e2="DDI-PubMed.31493066.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31493066.s2.e0" e2="DDI-PubMed.31493066.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31493066.s2.e1" e2="DDI-PubMed.31493066.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31493066.s2.e1" e2="DDI-PubMed.31493066.s2.e2" /></sentence><sentence text=" In this work, effects of MTX on the concentration of neonatal Fc receptor (FcRn) and the role of FcRn in the interaction between MTX and adalimumab were investigated"><entity charOffset="26-29" id="DDI-PubMed.31493066.s3.e0" text="MTX" /><entity charOffset="130-132" id="DDI-PubMed.31493066.s3.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.31493066.s3.e0" e2="DDI-PubMed.31493066.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31493066.s3.e0" e2="DDI-PubMed.31493066.s3.e1" /></sentence><sentence text="" /><sentence text="The experiment was performed in rats whose FcRn had normal physiological function and also in rats whose FcRn was blocked with FcRn antibody" /><sentence text=" Rats were randomly assigned to receive placebo or 0" /><sentence text="2 mg/kg MTX orally every week while taking one abdominal subcutaneous injection of 0"><entity charOffset="8-10" id="DDI-PubMed.31493066.s7.e0" text="MTX" /></sentence><sentence text="5 mg/kg adalimumab" /><sentence text=" The FcRn concentration in tissues and the PK parameters of adalimumab were compared between MTX-treated and placebo groups"><entity charOffset="93-95" id="DDI-PubMed.31493066.s9.e0" text="MTX" /></sentence><sentence text="" /><sentence text="In rats with normally functioning FcRn, the concentrations of FcRn were significantly increased in the liver (F=105" /><sentence text="5, p=0" /><sentence text="000) and kidney (F=996" /><sentence text="312, p=0" /><sentence text="000) after treatment with MTX, and the clearance (CL/F) of adalimumab was decreased accordingly (F=4"><entity charOffset="26-29" id="DDI-PubMed.31493066.s15.e0" text="MTX" /></sentence><sentence text="423, p=0" /><sentence text="048)" /><sentence text=" However, in rats injected with FcRn antibody, the concentrations of FcRn in MTX-treated rats were close to that of the placebo rats in the tissues of the liver (F=1"><entity charOffset="77-79" id="DDI-PubMed.31493066.s18.e0" text="MTX" /></sentence><sentence text="279, p=0" /><sentence text="268) and kidney (F=0" /><sentence text="661, p=0" /><sentence text="424)" /><sentence text=" The CL/F of adalimumab in rats was also not affected by MTX (F=0"><entity charOffset="13-23" id="DDI-PubMed.31493066.s23.e0" text="adalimumab" /><entity charOffset="57-60" id="DDI-PubMed.31493066.s23.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.31493066.s23.e0" e2="DDI-PubMed.31493066.s23.e0" /><pair ddi="false" e1="DDI-PubMed.31493066.s23.e0" e2="DDI-PubMed.31493066.s23.e1" /></sentence><sentence text="002, p=0" /><sentence text="961)" /><sentence text="" /><sentence text="FcRn may play a vital role in the interaction between adalimumab and MTX"><entity charOffset="69-71" id="DDI-PubMed.31493066.s27.e0" text="MTX" /></sentence><sentence text="" /></document>